Drilldown: Medicines

None (2) · Chlorhexidine gluconate (CHG) (1) · Irbesartan (1) · Telmisartan (1)

Ajovy (1) · Avapro (1) · Emgality (1) · Hibiclens, Hibistat, Peridex (dental rinse), ChloraPrep (1) · Micardis (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (2) · [[:Category:Antihypertensives|Antihypertensive]] (2) · [[:Category:Antiseptics|Antiseptic]] (1) · [[:Category:Bisbiguanides|Bisbiguanide]] (1)

None (1) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · '"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'. (1) · '"`UNIQ--vote-00000AEA-QINU`"' The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence'"`UNIQ--ref-00000AEB-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"' (1) · '"`UNIQ--vote-00000AEC-QINU`"', '"`UNIQ--vote-00000AED-QINU`"' (1) · '"`UNIQ--vote-00001393-QINU`"', '"`UNIQ--vote-00001394-QINU`"', '"`UNIQ--vote-00001395-QINU`"', '"`UNIQ--vote-00001396-QINU`"', '"`UNIQ--vote-00001397-QINU`"' (1)

150 mg PO once daily; titrate to 300 mg if needed (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 40 mg PO once daily; titrate to 80 mg (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) · Surgical scrub 4% CHG; preop skin prep 2% CHG/70% isopropyl alcohol (ChloraPrep); ICU bathing 2% CHG daily; oral rinse 0.12% 15 mL twice daily for 30 seconds (1)

120 mg/mL prefilled syringe or autoinjector (1) · 2%, 4% wash; 2% CHG/70% IPA applicators (ChloraPrep); 0.12%, 0.2% oral rinse; impregnated catheter dressings (1) · 20, 40, 80 mg tablets (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 75, 150, 300 mg tablets (1)

240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 300 mg/d (1) · 675 mg/quarter (1) · 80 mg/d (1) · Per formulation (1)

Oral (2) · oral rinse (do not swallow) (1) · Subcutaneous (2) · Topical (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 hours (2) · Monthly dosing (1) · Monthly or quarterly dosing (1) · Persistent activity 6+ hours (residual binding to skin and oral surfaces) (1)

11-15 hours'"`UNIQ--ref-00000842-QINU`"' (1) · Not meaningfully described (negligible systemic absorption from intact skin or oral mucosa)'"`UNIQ--ref-00001398-QINU`"' (1) · ~24 hours (longest of the ARB class; suits patients with morning BP surge)'"`UNIQ--ref-00000AEE-QINU`"' (1) · ~27 days (1) · ~31 days (1)

42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"' (1) · 60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"' (1) · Not formally established (1) · Not formally established (high SC) (1) · Topical/oral local action with minimal systemic absorption'"`UNIQ--ref-00001399-QINU`"' (1)

'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000844-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000AF0-QINU`"' (1) · Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; avoid (2)

OTC (lower-concentration washes) and [[USLegal:Prescription only|Rx-only]] (Peridex oral rinse, ChloraPrep) in US (1) · Rx (2) · [[USLegal:Prescription only|Rx-only]] in US (2)